We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Israeli drugmaker Protalix Biotherapeutics has announced it completed Phase I clinical trial for its drug for the treatment of Gaucher disease, with satisfactory results.
Merck has announced that a state court jury in New Jersey found in its favor, rejecting the claims of a patient who blamed her heart attack on nearly three years of Vioxx use.
Dutch biopharmaceutical company IQ Corporation (IQ) announces the successful completion of PER.C6 clone generation for the production of its two fully human monoclonal antibodies against the anthrax lethal toxin components Lethal Factor and Protective Antigen.
MERCK Sharp & Dohme, a global research-based pharmaceutical company, and Shanghai Biochip Co Ltd, one of China's biggest biotech firms, will cooperate in genetic research that seeks to create personalized therapies for cancer patients, the companies said.
Dishman Pharmaceuticals & Chemicals Ltd has informed that Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO) has joined as a Joint Venture partner in Saudi Arabian Joint Venture formed by the Company alongwith Arab Company for Drug Industries and Medical Appliances (ACDIMA) and Takamul Holding Company (THC) for new API project.
Abraxis BioScience, Inc., an integrated, global biopharmaceutical company, today announced that it has received a $3 million milestone payment from Taiho Pharmaceutical Co., Ltd., (Taiho), for initiation of a Phase 1 clinical trial for ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound).
Nastech Pharmaceutical announced Thursday morning that it received written notification from the FDA, on July 10, that the company's abbreviated new drug application for intranasal calcitonin-salmon is not approvable at this time.